Published in:
01-12-2014
Impact of treatment satisfaction on quality of life of patients with acromegaly
Authors:
Hasan Kepicoglu, Esra Hatipoglu, Irem Bulut, Ezgi Darici, Naz Hizli, Pinar Kadioglu
Published in:
Pituitary
|
Issue 6/2014
Login to get access
Abstract
Purpose
To evaluate satisfaction of acromegalic subjects with their medical treatment and its contribution to their quality of life.
Methods
This cross-sectional study included a total of 159 medications used in 133 subjects with acromegaly (controlled n = 84 and uncontrolled n = 49, female/male: 81/52). Subjects were asked to complete questionnaires on symptoms of depression (BDI) and satisfaction with the medical therapy they received for acromegaly (TSQM). Acromegaly cases also completed Acromegaly Quality of Life Questionnaire (AcroQoL).
Results
Subjects on pegvisomant therapy scored lower on convenience (p = 0.007). Cases on combination therapy had lower domain scores for effectiveness, convenience and global satisfaction in comparison to the cases on monotherapy (p = 0.01, p = 0.01 and p = 0.01, respectively). The time elapsed since diagnosis and the duration of medical therapy were positively correlated with effectiveness score (r = 0.2, p = 0.007 and r = 0.2, p = 0.04, respectively). The AcroQoL score was positively correlated with all domains of TSQM (for effectiveness r = 0.2, p = 0.01; for side effects r = 0.3, p = 0.001; for convenience r = 0.3, p = 0.004 and for global satisfaction r = 0.2, p = 0.01). In contrast, the BDI score was inversely correlated with all domains of TSQM (for effectiveness r = −0.3, p = 0.001; for side effects r = −0.2, p = 0.006; for convenience r = −0.3, p < 0.001 and for global satisfaction r = −0.3, p = 0.001).
Conclusion
In acromegaly, quality of life, status of depression and satisfaction of the subjects with their treatment are intercorrelated.